BR112017017284A2 - protease de cisteína - Google Patents

protease de cisteína

Info

Publication number
BR112017017284A2
BR112017017284A2 BR112017017284A BR112017017284A BR112017017284A2 BR 112017017284 A2 BR112017017284 A2 BR 112017017284A2 BR 112017017284 A BR112017017284 A BR 112017017284A BR 112017017284 A BR112017017284 A BR 112017017284A BR 112017017284 A2 BR112017017284 A2 BR 112017017284A2
Authority
BR
Brazil
Prior art keywords
cysteine protease
igg
vivo
methods
polypeptide
Prior art date
Application number
BR112017017284A
Other languages
English (en)
Inventor
Kjellman Christian
Nordahl Emma
JARNUM Sofia
Original Assignee
Hansa Medical Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hansa Medical Ab filed Critical Hansa Medical Ab
Publication of BR112017017284A2 publication Critical patent/BR112017017284A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/52—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/52—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea
    • C12N9/54—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea bacteria being Bacillus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Rheumatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Transplantation (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Emergency Medicine (AREA)

Abstract

a presente invenção refere-se a um novo polipéptido que exibe atividade de protease de cisteína de igg, e suas utilizações in vivo e ex vivo. as utilizações do polipéptido incluem métodos para a prevenção ou tratamento de doenças e condições mediadas por igg, e métodos para análise de igg.
BR112017017284A 2015-02-12 2016-02-12 protease de cisteína BR112017017284A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB201502306A GB201502306D0 (en) 2015-02-12 2015-02-12 Protein
PCT/EP2016/053052 WO2016128558A1 (en) 2015-02-12 2016-02-12 Cysteine protease

Publications (1)

Publication Number Publication Date
BR112017017284A2 true BR112017017284A2 (pt) 2018-04-17

Family

ID=52781456

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017017284A BR112017017284A2 (pt) 2015-02-12 2016-02-12 protease de cisteína

Country Status (23)

Country Link
US (4) US10696959B2 (pt)
EP (2) EP3256580B1 (pt)
JP (1) JP6961486B2 (pt)
KR (1) KR102524613B1 (pt)
CN (2) CN114231512A (pt)
AU (2) AU2016217800B2 (pt)
BR (1) BR112017017284A2 (pt)
CA (1) CA2976003A1 (pt)
CL (1) CL2017002065A1 (pt)
CO (1) CO2017009061A2 (pt)
DK (1) DK3256580T3 (pt)
EA (1) EA035130B1 (pt)
ES (1) ES2927234T3 (pt)
GB (1) GB201502306D0 (pt)
IL (1) IL253938B (pt)
LT (1) LT3256580T (pt)
MX (1) MX2017010390A (pt)
MY (1) MY188696A (pt)
PL (1) PL3256580T3 (pt)
PT (1) PT3256580T (pt)
SG (1) SG11201706346QA (pt)
WO (1) WO2016128558A1 (pt)
ZA (1) ZA201705113B (pt)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201502306D0 (en) * 2015-02-12 2015-04-01 Hansa Medical Ab Protein
GB201502305D0 (en) 2015-02-12 2015-04-01 Hansa Medical Ab Protein
US20210228738A1 (en) 2017-07-17 2021-07-29 INSERM (Institut National de la Santé et de la Recherche Médicale) Compositions and methods for increasing or enhancing transduction of gene therapy vectors and for removing or reducing immunoglobulins
KR20210006357A (ko) 2018-04-03 2021-01-18 스트라이드바이오 인코포레이티드 항체-회피 바이러스 벡터
MX2021011468A (es) 2019-03-21 2021-12-15 Vectores de virus adenoasociados recombinantes.
EP4038194A1 (en) 2019-10-04 2022-08-10 Ultragenyx Pharmaceutical Inc. Methods for improved therapeutic use of recombinant aav
US20230392163A1 (en) 2019-10-17 2023-12-07 Ginkgo Bioworks Inc. Adeno-associated viral vectors for treatment of niemann-pick disease type c
CA3172625A1 (en) 2019-12-06 2021-06-10 Regeneron Pharmaceuticals, Inc. Anti-vegf protein compositions and methods for producing the same
GB202002072D0 (en) 2020-02-14 2020-04-01 Hansa Biopharma AB immunoglobulin detection and associated therapies
JP2023514204A (ja) 2020-02-14 2023-04-05 ウルトラジェニックス ファーマシューティカル インコーポレイテッド Ｃｄｋｌ５欠損障害を処置するための遺伝子治療
GB202003129D0 (en) 2020-03-04 2020-04-15 Hansa Biopharma AB Conditioning regimen for transplant of stem cells
GB202007431D0 (en) * 2020-05-19 2020-07-01 Hansa Biopharma AB Cysteine protease
GB202007434D0 (en) 2020-05-19 2020-07-01 Hansa Biopharma AB Methods
JP2023529186A (ja) 2020-06-05 2023-07-07 上海宝済薬業有限公司 酵素とウィルスとの薬物組成物及びその使用
JP2023532219A (ja) * 2020-06-18 2023-07-27 上海宝済薬業有限公司 免疫グロブリン分解酵素ＩｄｅＥの突然変異体
JP2023545731A (ja) 2020-10-07 2023-10-31 アスクレピオス バイオファーマシューティカル， インコーポレイテッド 肢帯型２ｉ（ｌｇｍｄ２ｉ）を含むジストログリカノパチー障害を処置するためのフクチン関連タンパク質（ｆｋｒｐ）の治療的アデノ随伴ウイルス送達
JP2024515626A (ja) 2021-04-16 2024-04-10 アスクレピオス バイオファーマシューティカル， インコーポレイテッド 血液脳関門を横断し低減された液性応答を惹起する合理的ポリプロイドａａｖビリオン
EP4079848A1 (en) 2021-04-22 2022-10-26 Genovis Ab Immunoglobulin cleaving enzyme
WO2023019168A1 (en) 2021-08-11 2023-02-16 Ultragenyx Pharmaceutical Inc. Compositions and methods for treating a muscular dystrophy
CA3237815A1 (en) 2021-11-15 2023-05-19 Raghuveer RANGANATHAN Methods for enhancing adoptive cell transfer immunotherapies
WO2023116817A1 (zh) * 2021-12-22 2023-06-29 上海宝济药业有限公司 一种免疫球蛋白降解酶IdeE的突变体的用途
EP4275701A1 (en) 2022-05-13 2023-11-15 Hansa Biopharma AB Conditioning regimen for cell transplant
EP4302770A1 (en) 2022-07-08 2024-01-10 Hansa Biopharma AB Regimen for enzymatic desensitisation
EP4349365A1 (en) 2022-10-07 2024-04-10 Hansa Biopharma AB Co-treatment for gene therapy
CN115873833A (zh) * 2022-11-08 2023-03-31 上海泰昶生物技术有限公司 生产免疫球蛋白g降解酶的工程菌株和工艺
CN115998690A (zh) * 2022-11-10 2023-04-25 上海泰昶生物技术有限公司 包含免疫球蛋白g降解酶的冻干制剂及其制备工艺

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4366241A (en) 1980-08-07 1982-12-28 Syva Company Concentrating zone method in heterogeneous immunoassays
US6800744B1 (en) * 1997-07-02 2004-10-05 Genome Therapeutics Corporation Nucleic acid and amino acid sequences relating to Streptococcus pneumoniae for diagnostics and therapeutics
ES2307564T3 (es) 2000-12-21 2008-12-01 Id Biomedical Corporation Antigenos de streptococcus pyrogenes y fragmentos de adn correspondientes.
GB0130228D0 (en) * 2001-12-18 2002-02-06 Hansa Medica Ab Protein
ATE441715T1 (de) * 2003-03-04 2009-09-15 Intercell Ag Streptococcus pyogenes antigene
GB0511769D0 (en) * 2005-06-09 2005-07-20 Hansa Medical Ab Treatment
JP5427409B2 (ja) 2005-06-09 2014-02-26 ハンサ メディカル アクチボラゲット 自己免疫疾患及び移植片拒絶反応を治療するためのＩｄｅＳプロテイナーゼ（化膿連鎖球菌由来）の使用
US7544577B2 (en) 2005-08-26 2009-06-09 International Business Machines Corporation Mobility enhancement in SiGe heterojunction bipolar transistors
CN101889082A (zh) 2007-09-14 2010-11-17 季诺维斯公司 用于解离Fcgamma-受体-IgG复合物以及纯化与检测IgG的方法和试剂盒
WO2009075646A1 (en) 2007-12-13 2009-06-18 Bengt Guss Improved immunizing composition
ES2388017T3 (es) 2007-12-21 2012-10-05 Roche Glycart Ag Ensayo de estabilidad de anticuerpos
ES2535963T3 (es) 2009-02-09 2015-05-19 Roche Glycart Ag Análisis del patrón de glicosilación de inmunoglobulina
CA2799136A1 (en) 2010-05-26 2011-12-01 Intervacc Ab Vaccine against streptococcal infections based on recombinant proteins
GB201115841D0 (en) 2011-09-13 2011-10-26 Genovis Ab Protein and method
GB201201314D0 (en) 2012-01-26 2012-03-07 Isis Innovation Composition
CN103214549B (zh) * 2013-01-15 2015-08-05 珠海市丽珠单抗生物技术有限公司 一种还原免疫球蛋白的方法及其试剂盒
GB201316744D0 (en) 2013-09-20 2013-11-06 Genovis Ab Method
GB201413240D0 (en) 2014-07-25 2014-09-10 Hansa Medical Ab Method
GB201502306D0 (en) * 2015-02-12 2015-04-01 Hansa Medical Ab Protein
GB201502305D0 (en) 2015-02-12 2015-04-01 Hansa Medical Ab Protein

Also Published As

Publication number Publication date
CO2017009061A2 (es) 2018-01-16
AU2016217800A1 (en) 2017-08-10
IL253938A0 (en) 2017-10-31
EP4108768A1 (en) 2022-12-28
AU2016217800B2 (en) 2021-08-12
ZA201705113B (en) 2024-01-31
US11667905B2 (en) 2023-06-06
EA035130B1 (ru) 2020-04-30
KR20170116137A (ko) 2017-10-18
US11214784B2 (en) 2022-01-04
PT3256580T (pt) 2022-10-03
MY188696A (en) 2021-12-23
US20180023070A1 (en) 2018-01-25
IL253938B (en) 2020-01-30
US20230357741A1 (en) 2023-11-09
EP3256580A1 (en) 2017-12-20
DK3256580T3 (en) 2022-10-03
LT3256580T (lt) 2022-10-10
GB201502306D0 (en) 2015-04-01
US20220170004A1 (en) 2022-06-02
CN107532156A (zh) 2018-01-02
CN114231512A (zh) 2022-03-25
JP2018506286A (ja) 2018-03-08
PL3256580T3 (pl) 2022-11-28
EP3256580B1 (en) 2022-07-06
US10696959B2 (en) 2020-06-30
CA2976003A1 (en) 2016-08-18
KR102524613B1 (ko) 2023-04-21
SG11201706346QA (en) 2017-09-28
ES2927234T3 (es) 2022-11-03
WO2016128558A1 (en) 2016-08-18
CL2017002065A1 (es) 2018-04-02
JP6961486B2 (ja) 2021-11-05
AU2021266293A1 (en) 2021-12-09
EA201791773A1 (ru) 2018-02-28
US20200283749A1 (en) 2020-09-10
MX2017010390A (es) 2017-12-07

Similar Documents

Publication Publication Date Title
BR112017017286A2 (pt) protease de cisteína
BR112017017284A2 (pt) protease de cisteína
BR112019006876A2 (pt) anticorpos e composições anti-lag-3
CL2018003142A1 (es) Moduladores de la vía de estrés integrada
GT201700081A (es) Moléculas de anticuerpo que se unen a pd-l1 y usos de las mismas
BR112019006160A2 (pt) composições e métodos para o tratamento das condições oftálmicas
CU20160185A7 (es) Compuestos de heteroarilo para la inhibición de cinasa
PH12016501441A1 (en) Chimeric alkaline phosphate-like proteins
EA201790405A1 (ru) Композиции и способы лечения метаболических расстройств
EA201691582A1 (ru) Новые фармацевтические препараты
BR112015019995A2 (pt) Combinação terapêutica envolvendo anticorpos contra claudina 18.2 para tratamento de câncer
EA201891539A1 (ru) Соединения, ингибирующие металлоферменты
BR112016025819A2 (pt) vetores de vírus adeno-associados para o tratamento de doenças de depósito lisossômico
BR112015030356A2 (pt) métodos de tratamento de uma taupatia
BR112017004893A2 (pt) composições e métodos para o tratamento de lesões cutâneas pré-cancerosas
BR112018011504A2 (pt) microcápsulas de trombina
BR112017018522A2 (pt) composições e métodos para diagnóstico e tratamento do câncer
BR112019001039A2 (pt) composição para uso no tratamento de transtorno depressivo maior
BR112016024096A2 (pt) novo bacteriófago e composição compreendendo o mesmo
BR112018003780A2 (pt) composições que compreendem um composto de urolitina
CO2017001087A2 (es) Anticuerpos anti proteína similar a angiopoyetina 4
EA201992170A1 (ru) Модуляторы экспрессии pcsk9
BR112017014416A2 (pt) sal de mangiferina-6-o-berberina e método de preparação e uso do mesmo
BR112019002458A2 (pt) composições e métodos para tratar câncer com depleção de arginina e agentes imuno-oncológicos
BR112016019286A2 (pt) anticorpos do componente c5 do complemento

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B25F Entry of change of name and/or headquarter and transfer of application, patent and certif. of addition of invention: change of name on requirement

Owner name: HANSA MEDICAL AB (SE)

Free format text: A FIM DE ATENDER A ALTERACAO DE NOME REQUERIDA ATRAVES DA PETICAO NO 870210073636, DE 12/08/2021, E NECESSARIO APRESENTAR DOCUMENTO NOTARIZADO E COM APOSTILAMENTO OU LEGALIZACAO CONSULAR, ALEM DA GUIA DE CUMPRIMENTO DE EXIGENCIA.

B25D Requested change of name of applicant approved

Owner name: HANSA BIOPHARMA AB (SE)

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]